Abstract
Mutations in certain genes that regulate the cell cycle, such as p16 and p53, are frequently found in human cancers. However, tumor-specific mutations are uncommon in genes encoding cyclin E and the CDK inhibitor p27Kip1, two cell-cycle regulators that are also thought to contribute to tumor progression. It is now known that levels of both cyclin E and p27 can be controlled by posttranscriptional mechanisms, indicating that expression of these proteins can be altered by means other than simply mutation of their respective genes. Thus, changes in p27 and cyclin E protein levels in tumors might be more common than previously anticipated and may be indicators of tumor behavior.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Biomarkers, Tumor
-
Breast Neoplasms / genetics*
-
Breast Neoplasms / mortality
-
Breast Neoplasms / pathology
-
Carcinoma, Ductal, Breast / genetics*
-
Carcinoma, Ductal, Breast / mortality
-
Carcinoma, Ductal, Breast / pathology
-
Cell Cycle Proteins*
-
Cyclin-Dependent Kinase Inhibitor p27
-
Cyclins / genetics*
-
Female
-
Gene Expression*
-
Genes, cdc*
-
Humans
-
Microtubule-Associated Proteins / genetics*
-
Prognosis
-
Survival Analysis
-
Tumor Suppressor Proteins*
Substances
-
Biomarkers, Tumor
-
Cell Cycle Proteins
-
Cyclins
-
Microtubule-Associated Proteins
-
Tumor Suppressor Proteins
-
Cyclin-Dependent Kinase Inhibitor p27